| EPA080 | Impact of chronic HCV infection on CD4-T cells permissiveness to HIV infection and viral reservoir persistence | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPA081 | HPV circulating tumoural DNA as a potential biomarker to monitor anal lesions in HIV-infected men who have sex with men (MSM) | E-poster | HIV and co-infections (TB, viral hepatitis, SARS-CoV2, other) |
| EPB122 | Non-invasive identification of severe NAFLD and risk stratification of clinical outcomes using Fibroscan-AST (FAST) score in 1683 people with HIV | E-poster | Hepatic complications (e.g., NASH) |
| EPB123 | Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand | E-poster | Hepatic complications (e.g., NASH) |
| PESUB18 | PROGRESSION OF HEPATIC STEATOSIS IN PEOPLE WITH HIV ON INTEGRASE INHIBITORS | Poster exhibition | Hepatic complications (e.g., NASH) |
| EPD263 | A qualitative study of people who use new psychoactive substances and harm reduction services in eight countries of the Eastern Europe and Central Asia region | E-poster | Harm reduction |
| EPD264 | Montreal overdose crisis: a collaborative response by and for communities | E-poster | Harm reduction |
| EPD265 | Perspectives on perceived barriers and benefits of integration of harm reduction services and PrEP among people who use drugs in Uganda | E-poster | Harm reduction |
| EPD266 | CHEMSEX: KONTAK & ImpakT, programs adapting to the reality and needs, of men who fuck men on drugs | E-poster | Harm reduction |
| EPD267 | Building a harm reduction-based hospital | E-poster | Harm reduction |